2005 - Fellow of American Physical Society (APS) Citation For insightful contributions to the theoretical description and the interpretation of experimental data of quantum fluid mixtures and mixture films
Michael D. Miller mainly focuses on Virology, Internal medicine, Reverse transcriptase, Immunology and Hepatitis B virus. All of his Virology and Viral replication, Lamivudine, Reverse-transcriptase inhibitor, Lentivirus and Virus investigations are sub-components of the entire Virology study. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Raltegravir.
Michael D. Miller combines subjects such as Integrase and Viral load with his study of Raltegravir. His Reverse transcriptase research incorporates elements of Molecular biology and Polymerase, DNA. His studies examine the connections between Immunology and genetics, as well as such issues in Pharmacotherapy, with regards to Antiretroviral treatment, Prospective cohort study and Retrospective cohort study.
His primary areas of investigation include Virology, Reverse transcriptase, Internal medicine, Virus and Reverse-transcriptase inhibitor. His Virology research includes themes of Resistance mutation, Drug resistance and Genotype. The Drug resistance study which covers Integrase that intersects with Raltegravir Potassium.
The Reverse transcriptase study combines topics in areas such as Mutation, Mutant, Molecular biology, Viral replication and Lentivirus. His studies in Internal medicine integrate themes in fields like Gastroenterology, Viral load and Oncology. Michael D. Miller has researched Reverse-transcriptase inhibitor in several fields, including Zidovudine and Nucleotidyltransferase.
Michael D. Miller spends much of his time researching Virology, Genotype, Drug resistance, Emtricitabine and Internal medicine. Virology is closely attributed to Elvitegravir in his research. His Drug resistance study incorporates themes from Hepatitis B, Lamivudine, Hepatitis B virus and Reverse transcriptase.
As part of the same scientific family, he usually focuses on Reverse transcriptase, concentrating on Molecular biology and intersecting with Cell and In vitro. His Emtricitabine research is multidisciplinary, incorporating elements of Tenofovir alafenamide, Regimen, Efavirenz, Resistance mutation and Pharmacology. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Viremia and Viral load.
The scientist’s investigation covers issues in Virology, Hepatitis C virus, Sofosbuvir, Genotype and Drug resistance. His study in Virus, Ribavirin, NS5A, Reverse-transcriptase inhibitor and Viral replication is carried out as part of his studies in Virology. His biological study spans a wide range of topics, including NS5B, Gastroenterology, Internal medicine, Hepatitis C and Ledipasvir.
His studies deal with areas such as Regimen and Clinical trial as well as Genotype. His work deals with themes such as Hepatitis B virus and Emtricitabine, which intersect with Drug resistance. His research in Emtricitabine intersects with topics in Hepatitis B and Adefovir.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Joel E. Gallant;Schlomo Staszewski;Anton L. Pozniak;Edwin DeJesus.
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Daria J. Hazuda;Peter Felock;Marc Witmer;Abigail Wolfe.
Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines.
Critical Reviews in Immunology (1992)
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition.
Michael D. Miller;Chris M. Farnet;Frederic D. Bushman.
Journal of Virology (1997)
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron.
The New England Journal of Medicine (2008)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard.
The Lancet (2009)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh.
The New England Journal of Medicine (2008)
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Martin Markowitz;Bach-Yen Nguyen;Eduardo Gotuzzo;Fernando Mendo.
Journal of Acquired Immune Deficiency Syndromes (2007)
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan
Victor DeGruttola;Lynn Dix;Richard D'Aquila;Dan Holder.
Antiviral Therapy (2000)
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
Daria J. Hazuda;Neville J. Anthony;Robert P. Gomez;Samson M. Jolly.
Proceedings of the National Academy of Sciences of the United States of America (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: